| REVIEW ARTICLE |
|
| Year : 2020 | Volume
: 7
| Issue : 1 | Page : 7-25 |
|
|
Adjuvant therapy in assisted reproduction treatment (ART): Current evidence and recommendations for clinical practice
Sohani Verma
Sr Consultant Obstetrician and Gynaecologist, Infertility & ART Specialist, Indraprastha Apollo Hospitals, India
Correspondence Address:
Dr. Sohani Verma
Indraprastha Apollo Hospitals, Delhi-Mathura Road, New Delhi-110076
India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/2394-4285.288706
|
|
|
There is an ever-growing list of a wide variety of pharmacological agents and interventions being implicated as adjuvant therapies alongside the core fertilization techniques—IVF or ICSI. Most of the data to support use of these adjuvant therapies are based on anecdotal, heterogeneous, and underpowered studies and associated with controversial results. Clinicians should be fully aware of the best available current evidence and patients must be informed about the experimental nature of any adjuvant therapy being offered to them, when there is no robust evidence of its safety and/or effectiveness. Any adjuvant therapy should be offered only if there is potential for cost-effective, physiological, and psychological benefit and a minimum risk of harm. Further research in the form of good quality preferably RCTs on a large number of infertile couples is required to establish true effectiveness and safety of various adjuvant therapies.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
